Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0106213793
Wed, 17.04.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, April 17, 2024
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
The Western District Court of the Canton Basel-Landschaft has granted Spexis [ … ]
Thu, 08.02.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, February 8, 2024
Spexis announces closing of sale of preclinical antibiotics program to Basilea
Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains
Transaction is part of S [ … ]
Mon, 15.01.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, January 15, 2024
Spexis announces sale of preclinical antibiotics program to Basilea
Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains
Preclinical studies demonstrated ba [ … ]
Tue, 05.12.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Spexis is Granted Debt-Restructuring Moratorium
Allschwil, Switzerland, December 5, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it has been formally granted moratorium status (Nachlassstu [ … ]
Wed, 29.11.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Spexis Provides Update Regarding Debt-Restructuring Moratorium
Allschwil, Switzerland, November 29, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it is in discussions with SPRIM Global [ … ]
Wed, 08.11.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, November 8, 2023
Spexis to file an application for a debt-restructuring moratorium
Spexis AG (SIX: SPEX) is in the process of filing an application for a debt-restructuring moratorium with the Western District Court of the Canton Basel-Landschaft.
As previously reported in [ … ]
Wed, 01.11.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Spexis Announces Changes to the Executive Committee
Allschwil, Switzerland, November 1, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Financial Officer [ … ]
Fri, 06.10.2023
Spexis AG
Spexis AG
/ Key word(s): Statement
Spexis to host business update conference call on October 9, 2023
06.10.2023 / 07:30 CET/CEST
Spexis to host business update conference call on October 9, 2023
Allschwil, Switzerland, October 6, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical comp [ … ]
Fri, 29.09.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Spexis provides business update and announces financial results for the first half of 2023
Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Spexis closed capital commitments totaling USD $7.5 million supporting Phase 3 Coli [ … ]
Thu, 28.09.2023
Spexis AG
Spexis AG
/ Key word(s): Statement
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
28.09.2023 / 07:30 CET/CEST
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
Allschwil, Switzerland, September 28, 2023
Spexis [ … ]